drugset / Trial / NCT04508907

A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients

NCT04508907

Phase 4 Active not recruiting 200 enrolled Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.

Timeline

Start
2020-09-10
Primary completion
2025-11-01
Completion
2026-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown
Subject glecaprevir Other / unclassified